Page 22 - Demo

Disease-free survival by subgroups22AKLPembrolizumab Placebo Hazard Ratio for Death (95% CI) no. of events/no. of participantsOverall 174/496 224/498 0.72 (0.59%u20140.87)Age <65 yrs >65 yrs117/33857/158135/32689/1720.77 (0.60%u20140.98)0.67 (0.48%u20140.93)Sex Female Male50/149124/34763/139161/3590.68 (0.47%u20140.99)0.74 (0.59%u20140.94)Race White All others130/37233/88170/37641/870.73 (0.58%u20140.91)0.72 (0.45%u20141.13)ECOG performance-status score 0 1147/42127/75188/42636/720.73 (0.59%u20140.90)0.71 (0.43%u20141.16)PD-L1 combined positive score CPS <1 CPS >137/124133/36536/113187/3830.91 (0.58%u20141.44)0.68 (0.55%u20140.85)Geographic region United States Other38/114136/38255/117169/3810.69 (0.46%u20141.05)0.74 (0.59%u20140.92)Metastatic staging M0 M1 NED161/46713/29203/47021/280.75 (0.61%u20140.93)0.40 (0.20%u20140.81)Disease risk category M0 intermediate-to-high risk M0 high risk M1 NED138/42222/4013/29177/43326/3721/280.76 (0.61%u20140.95)0.61 (0.35%u20141.08)0.40 (0.20%u20140.81)Sarcomatoid features Present Absent22/52139/41433/59179/4150.63 (0.37%u20141.08)0.73 (0.59%u20140.91)0.1 0.5 1.0 1.5Favours Pembrolizumab Favours PlaceboArrows indicate that the confidence interval extends outside the graphed area.CI, confidence interval; CPS, combined positive score; ECOG, Eastern Cooperative Oncology Group; NED, no evidence of disease; PD-L1, programmed death-ligand 1.Choueiri et al. N Engl J Med 2024;390:1359-1371.